CABA
Price
$3.02
Change
+$0.02 (+0.66%)
Updated
Jun 23, 04:04 PM (EDT)
Capitalization
489.16M
44 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.75
Change
-$0.05 (-1.79%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
427.39M
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CABA vs EDIT

CABA vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CABA vs. EDIT commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (CABA: $3.00 vs. EDIT: $2.79)
Brand notoriety: CABA and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 128% vs. EDIT: 123%
Market capitalization -- CABA: $489.16M vs. EDIT: $427.39M
CABA [@Biotechnology] is valued at $489.16M. EDIT’s [@Biotechnology] market capitalization is $427.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • CABA’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, CABA is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 4 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • CABA’s TA Score: 4 bullish, 6 bearish.
  • EDIT’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CABA is a better buy in the short-term than EDIT.

Price Growth

CABA (@Biotechnology) experienced а -0.33% price change this week, while EDIT (@Biotechnology) price change was +13.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.

Reported Earning Dates

CABA is expected to report earnings on Aug 06, 2026.

EDIT is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Biotechnology (+7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CABA($489M) has a higher market cap than EDIT($427M). CABA (36.986) and EDIT (35.854) have similar YTD gains . EDIT has higher annual earnings (EBITDA): -100.08M vs. CABA (-171.58M). EDIT has more cash in the bank: 124M vs. CABA (117M). EDIT has less debt than CABA: EDIT (17.3M) vs CABA (26.4M). EDIT has higher revenues than CABA: EDIT (38.7M) vs CABA (0).
CABAEDITCABA / EDIT
Capitalization489M427M115%
EBITDA-171.58M-100.08M171%
Gain YTD36.98635.854103%
P/E RatioN/AN/A-
Revenue038.7M-
Total Cash117M124M94%
Total Debt26.4M17.3M153%
FUNDAMENTALS RATINGS
CABA vs EDIT: Fundamental Ratings
CABA
EDIT
OUTLOOK RATING
1..100
2786
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5146
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
790

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (36) in the null industry is somewhat better than the same rating for EDIT (87) in the Biotechnology industry. This means that CABA’s stock grew somewhat faster than EDIT’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to EDIT’s over the last 12 months.

CABA's SMR Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (46) in the Biotechnology industry is in the same range as CABA (51) in the null industry. This means that EDIT’s stock grew similarly to CABA’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CABA (100) in the null industry. This means that EDIT’s stock grew similarly to CABA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CABAEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
89%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CABA
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HBGIX24.36N/A
N/A
Hartford Disciplined Equity HLS IB
ATGAX46.90N/A
N/A
Cantor Fitzgerald Equity Opp A
EIIFX12.82N/A
N/A
Eaton Vance Balanced I
GPGOX3.82N/A
N/A
Grandeur Peak Global Opportunities Inv
GQGRX18.76N/A
N/A
GQG Partners Emerging Markets Equity R6

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with NKTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
+5.63%
NKTX - CABA
42%
Loosely correlated
-2.27%
FATE - CABA
42%
Loosely correlated
+2.39%
NCEL - CABA
41%
Loosely correlated
+5.44%
CGEM - CABA
40%
Loosely correlated
+15.10%
EDIT - CABA
39%
Loosely correlated
+3.53%
More